



(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/032343

(22) International Filing Date:

13 May 2021 (13.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/024,416	13 May 2020 (13.05.2020)	US
63/035,649	05 June 2020 (05.06.2020)	US
63/047,828	02 July 2020 (02.07.2020)	US
63/164,294	22 March 2021 (22.03.2021)	US

(71) Applicants: **DISC MEDICINE, INC.** [US/US]; 150 Cambridgepark Drive, Suite 103, Cambridge, MA 02140 (US). **ABBVIE DEUTSCHLAND GMBH & CO. KG** [DE/DE]; Mainzer Str. 81, 65189 Wiesbaden (DE). **ABBVIE INC.** [US/US]; 1 N. Waukegan Road, North Chicago, IL 60064 (US).

(72) Inventors: **BECONI, Maria**; 150 Cambridgepark Drive, Suite 103, Cambridge, MA 02140 (US). **QUISEL, John**;

150 Cambridgepark Drive, Suite 103, Cambridge, MA 02140 (US). **MACDONALD, Brian**; 19 Paper Mill Rd, Newton Square, PA 19073 (US). **ROBINETTE, Steven**; 89 Scribner Road, Fremont, NH 03044 (US). **MUELLER, Bernhard**; Im Eichholz 24a, 30657 Hannover (DE). **POPP, Andreas**; C/o Abbvie Deutschland GmbH & Co. Kg, Knollstrasse 50, 67061 Ludwigshafen (DE). **PEREZ, Jennifer, M.**; 400 Technology Square, 10th Floor, Cambridge, MA 02139 (US).

(74) Agent: **GE, Lingyin** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS

(57) Abstract: Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and/or conditions associated with myelofibrosis.




FIG. 13

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))